REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of [•] by and among [•] (the “Company”)1, and each of the holders of Registrable Securities listed on Schedule A hereto, which shall include KKR and Viking, each of which is referred to in this Agreement as a “Holder,” and any additional holders that becomes a party to this Agreement in accordance with Section 4.1 hereof.2
S09-398 : CKC EXCLUSIVE (EQUITY) AGREEMENT CONFIDENTIALExclusive (Equity) Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • California
This Exclusive (Equity) Agreement (this “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Eidos Therapeutics, Inc. (“Eidos”), a corporation having a principal place of business at 12354 Skyline Boulevard, Woodside, CA 94062, is effective on the 10th day of April, 2016 (“Effective Date”).
ASSET PURCHASE AGREEMENT among PHOENIX TISSUE REPAIR, INC., SHIRE HUMAN GENETIC THERAPIES, INC. and LOTUS TISSUE REPAIR, INC. Dated as of July 21, 2017Asset Purchase Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT, dated as of July 21, 2017, is made and entered into by and among PHOENIX TISSUE REPAIR, INC., a Delaware corporation (“Purchaser”), SHIRE HUMAN GENETIC THERAPIES, INC., a Delaware corporation (“Shire”), and LOTUS TISSUE REPAIR, INC., a Delaware corporation (“Lotus,” and together with Shire, “Sellers” or each a “Seller”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in Section 7.06(b).
FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF BRIDGEBIO PHARMA LLC a Delaware Limited Liability Company Dated as of November 20, 2018Limited Liability Company Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • Delaware
This FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (the “Agreement”) of BridgeBio Pharma LLC, a Delaware limited liability company (the “Company”), is made and entered into as of November 20, 2018 (the “Effective Date”), by and among KKR Genetic Disorder L.P., a Delaware limited partnership (together with its successors and assigns, the “KKR Member” or “KKR”), each Person listed on Exhibit A hereto as of the Effective Date as a New Member (the “New Members”), each Person listed on Exhibit A hereto as of the Effective Date as an Existing Member (the “Existing Members”), and each Additional Member and Substitute Member from time to time admitted in accordance with this Agreement, in each case for so long such party remains a Member of the Company. The Company is organized under the Delaware Limited Liability Company Act, 6 Del.C. § 18-101, et seq. (as amended from time to time, the “Act”).
LICENSE AGREEMENTLicense Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • Massachusetts
This License Agreement (“Agreement”), made as of January 29, 2018 (“Effective Date”), is by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and QED Therapeutics, Inc., a Delaware corporation located at 421 Kipling Street, Palo Alto, CA 94301 USA (“QED”). Novartis and QED are each referred to individually as a “Party” and together as the “Parties.”
ContractPatent License Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • Maryland
[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
COLLABORATION AND LICENSE AGREEMENT by and among The University of Texas M.D. Anderson Cancer Center, The Board of Regents of the University of Texas System, And PTP Pharmaceuticals, Inc.Collaboration and License Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • Texas
This Agreement is effective as of March 3, 2017 (the “Effective Date”), by and among The Board of Regents (“Board”) of The University of Texas System (“System”), The University of Texas M.D. Anderson Cancer Center, a member institution of System and an agency of the State of Texas, with offices at 1515 Holcombe Blvd., Houston, Texas 77030 (“MDACC”), and PTP Pharmaceuticals, Inc., a Delaware corporation located at 165 University Avenue, Suite #5, Palo Alto, CA 94301 (“Company”). Board, MDACC, and Company are each sometimes referred to herein as a “Party” or collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and TheRas, Inc. for Covalent Modification on CAAX- box Cysteine of K-Ras 4B Using Tethering Compounds UC Case No. [***]Exclusive License Agreement • April 16th, 2019 • BridgeBio Pharma LLC • Pharmaceutical preparations • California
This exclusive license agreement (“Agreement”) is made effective this 28th day of September, 2016 (“Effective Date”), by and between The Regents of the University of California, a California public corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”) and acting through its Office of Innovation, Technology, and Alliances, University of California San Francisco (“UCSF”), 3333 California Street, Suite S-11, San Francisco, CA 94143 and TheRas, Inc., a Delaware corporation, having a principal place of business at 165 University Avenue, Suite 5, Palo Alto, CA 94301 (“Licensee”) and a subsidiary of BridgeBio, LLC.
